A federally approved cardiac drug demonstrates significant efficacy in disrupting SARS-CoV-2 entry into the human cell host, according to a new study by a team of researchers from Texas A&M University and the University of Texas Medical Branch (UTMB).
The drug bepridil, which goes by the trade name Vascor, is currently approved by the US Food and Drug Administration (FDA) for the treatment of angina, a heart disease.
The team leaders are Professor of College of Science Wenshe Ray Liu, Professor and holder of the Gradipore Chair of the Department of Chemistry at Texas A&M, and Chien-Te Kent Tseng, Professor and Director of the SARS / MERS / COVID-1
“There is currently only one drug, Remdesivir, that provides COVID-19 patients with limited benefits, and the virus can easily avoid it,” Liu said. “It is imperative to find alternative medicines. Our team screened more than 30 FDA / European Medicines Agency approved medicines for their ability to inhibit the entry of SARS-COV-2 into human cells. The study showed that bepridil offers the greatest potential for treatment. of COVID-19. As a result, we advocate a serious consideration of the use of bepridil in clinical trials related to SARS-CoV-2. “
The Texas A&M UTMB survey is now available on the peer-reviewed website Proceedings of the National Academy of Sciences (PNAS) and is expected to be published on 9 March.
The team, which includes six other researchers from Texas A&M and four from UTMB, now plans to advance their work to animal models with the potential for clinical trials.
Follow the latest news on the outbreak of coronavirus (COVID-19)
Erol C. Vatansever et al., Bepridil is potent against SARS-CoV-2 in vitro, Proceedings of the National Academy of Sciences (2021). DOI: 10.1073 / pnas.2012201118
Provided by Texas A&M University
Citation: Research group identifies potential drug for treatment of SARS-CoV-2 (2021, February 22) retrieved February 23, 2021 from https://medicalxpress.com/news/2021-02-team-potential-drug-sars-cov- .html
This document is subject to copyright. Except for fair trade for private examination or research, no parts may be reproduced without written permission. The content is provided for informational purposes only.